实用临床医学
實用臨床醫學
실용림상의학
Practical Clinical Medicine
2015年
7期
15-17
,共3页
李伟镇%陈少娜%王思鸿%范泽潮
李偉鎮%陳少娜%王思鴻%範澤潮
리위진%진소나%왕사홍%범택조
慢性阻塞性肺疾病%沙美特罗%氟替卡松%百令胶囊%疗效
慢性阻塞性肺疾病%沙美特囉%氟替卡鬆%百令膠囊%療效
만성조새성폐질병%사미특라%불체잡송%백령효낭%료효
chronic obstructive pulmonary disease%salmeterol%fluticasone%corbrin capsule%clinical effect
目的:探讨舒利迭联合百令胶囊治疗慢性阻塞性肺疾病(COPD)的临床疗效。方法将90例慢性阻塞性肺疾病患者按随机数字表法分为2组:对照组45例行常规治疗+舒利迭,观察组45例在对照组治疗基础上给予百令胶囊。治疗12周后,比较2组肺功能指标、动脉血气指标及6 min 步行距离(6MWT)的变化情况。结果与治疗前比较,2组治疗后肺功能指标、动脉血气指标均明显改善(P <0.05),6MWT 值均明显升高(P <0.05);与对照组治疗后比较,观察组治疗后肺功能指标、动脉血气指标及6MWT 值改善更为显著(P <0.05)。结论舒利迭联合百令胶囊治疗 COPD 具有协同作用,更好地达到了对 COPD 的控制与治疗目的。
目的:探討舒利迭聯閤百令膠囊治療慢性阻塞性肺疾病(COPD)的臨床療效。方法將90例慢性阻塞性肺疾病患者按隨機數字錶法分為2組:對照組45例行常規治療+舒利迭,觀察組45例在對照組治療基礎上給予百令膠囊。治療12週後,比較2組肺功能指標、動脈血氣指標及6 min 步行距離(6MWT)的變化情況。結果與治療前比較,2組治療後肺功能指標、動脈血氣指標均明顯改善(P <0.05),6MWT 值均明顯升高(P <0.05);與對照組治療後比較,觀察組治療後肺功能指標、動脈血氣指標及6MWT 值改善更為顯著(P <0.05)。結論舒利迭聯閤百令膠囊治療 COPD 具有協同作用,更好地達到瞭對 COPD 的控製與治療目的。
목적:탐토서리질연합백령효낭치료만성조새성폐질병(COPD)적림상료효。방법장90례만성조새성폐질병환자안수궤수자표법분위2조:대조조45례행상규치료+서리질,관찰조45례재대조조치료기출상급여백령효낭。치료12주후,비교2조폐공능지표、동맥혈기지표급6 min 보행거리(6MWT)적변화정황。결과여치료전비교,2조치료후폐공능지표、동맥혈기지표균명현개선(P <0.05),6MWT 치균명현승고(P <0.05);여대조조치료후비교,관찰조치료후폐공능지표、동맥혈기지표급6MWT 치개선경위현저(P <0.05)。결론서리질연합백령효낭치료 COPD 구유협동작용,경호지체도료대 COPD 적공제여치료목적。
Objective To investigate the clinical effect of seretide combined with corbrin cap-sule on chronic obstructive pulmonary disease(COPD).Methods Ninety patients with COPD re-ceived conventional therapy.In addition,these patients were randomly treated with seretide alone (control group,n=45)or in combination with corbrin capsule(observation group,n=45).Lung function indices,arterial blood gas indexes and 6MWT were compared between the two groups af-ter treatment for 12 weeks.Results Lung function indices,arterial blood gas indexes and 6-mi-nute walk distance(6MWT)were significantly improved in both groups after treatment(P <0. 05),and the improvement in observation group was more obvious than that in control group(P <0.05).Conclusion Seretide and corbrin capsule have a synergistic effect on the control and treat-ment of COPD.